BrainsWay is an industry leader in the field of transcranial magnetic stimulation (TMS). BrainsWayâs flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US. The company also has approval in Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications. BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders. BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY. Source
No articles found.
Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the deve...
Citius Pharmaceuticals is a specialty pharmaceu...
China Biologic Products Holdings, Inc. (NASDAQ: CBPO), is a leading fully integrat...
China Biologic Products Holdings, Inc. (NASDAQ:...
Optinose is a specialty pharmaceutical company focused on creating and bringing to...
Optinose is a specialty pharmaceutical company ...
Pacific Biosciences' mission is to transform the way humankind acquires, processes...
Pacific Biosciences' mission is to transform th...
For more than 40 years, IntriCon has been meeting the rising demand for smaller, p...
For more than 40 years, IntriCon has been meeti...
Galectin Therapeutics is a biotechnology company focused on discovery and developm...
Galectin Therapeutics is a biotechnology compan...
Novocure is a global oncology company working to extend survival in some of the mo...
Novocure is a global oncology company working t...
Join the National Investor Network and get the latest information with your interests in mind.